An elephant among us: The role of dopamine in the pathophysiology of fibromyalgia

Journal of Rheumatology

Volumn 36, Issue 2, 2009, Pages 221-224

  Wood, Patrick B ^a   Holman, Andrew J ^b  

^a Angler Biomedical Technologies LLC   (United States)

^b Pacific Rheumatology Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DULOXETINE; FLUORODEOXYGLUCOSE F 18; MILNACIPRAN; OXYBATE SODIUM; PLACEBO; PRAMIPEXOLE; PREGABALIN; RACLOPRIDE C 11; ROPINIROLE; ROTIGOTINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; MU OPIATE RECEPTOR;

ANALGESIA; BEDTIME DOSAGE; CLINICAL TRIAL; DOPAMINERGIC ACTIVITY; DRUG APPROVAL; EDITORIAL; FATIGUE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HUMAN; LOW DRUG DOSE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; TIMED DRUG RELEASE; TREATMENT OUTCOME; ANIMAL; BRAIN; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SPINAL CORD; SYNAPTIC TRANSMISSION;

ANIMALS; BRAIN; DOPAMINE; DOPAMINE AGONISTS; FIBROMYALGIA; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE; RECEPTORS, OPIOID, MU; SPINAL CORD; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 64849105791     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080583     Document Type: Editorial

References (33)

1. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-541
2. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003;17:685-701. (Pubitemid 36869134)
3. Pani L, Porcella A, Gessa GL. The role of stress in the pathophysiology of the dopaminergic system. Mol Psychiatry 2000;5:14-21. (Pubitemid 30088448)
4. Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008;8:781-797
5. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-556
6. Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 1996;312:133. (Pubitemid 26158308)
7. Cervenka S, Pålhagen SE, Comley RA, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006;129:2017-2028 (Pubitemid 44289067)
8. Paulus W, Dowling P, Rijsman R, Stiasny-Kolster K, Trenkwalder C, de Weerd A. Pathophysiological concepts of restless legs syndrome. Mov Disord 2007;22:1451-1456 (Pubitemid 47280631)
9. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 2003;75:77-82. (Pubitemid 36645023)
10. Sorensen J, Bengtsson A, Bäckman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995;24:360-365 (Pubitemid 26041936)
11. Sorensen J, Bengtsson A, Ahlner J, Henriksson KG, Ekselius L, Bengtsson M. Fibromyalgia - are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1997;24:1615-1621 (Pubitemid 27320707)
12. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85:483-491 (Pubitemid 30214177)
13. Seeman P, Ko F, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 2005;10:877-883
14. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007;27:10000-10006 (Pubitemid 47404015)
15. Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci 1999;65:2269-2287 (Pubitemid 29531031)
16. Kim HS, Iyengar S, Wood PL. Opiate actions on mesocortical dopamine metabolism in the rat. Life Sci 1986;39:2033-2036 (Pubitemid 17184818)
17. Wood PB, Patterson JC 2nd, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007;8:51-58
18. Wood PB, Schweinhardt P, Jaeger E, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007;25:3576-3582 (Pubitemid 47020461)
19. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52:2495-2505 (Pubitemid 41117437)
20. Holman AJ. Treatment of fibromyalgia: a changing of the guard. Women's Health 2005;1:409-420
21. Holman AJ. Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind, pilot, randomized controlled trial with 14-week blinded extension [abstract]. Arthritis Rheum 2004;50 Suppl:S698.
22. GlaxoSmithKline. A randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety and efficacy of controlled-release ropinirole 1-24 mg q.d. administered for 12 weeks in subjects with fibromyalgia. Protocol summary of ROF102100. [Internet. Accessed October 12, 2008.] Available from: http://ctr.gsk.co.uk/Summary/Ropinirole/II-ROF102100. pdf
23. Dziedzicka-Wasylewska M, Ferrari F, Johnson RD, et al. Mechanisms of action of pramipexole: effects of receptors. Rev Contemp Pharmacother 2001;12:1-31. (Pubitemid 32538390)
24. Martinez-Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 2000;29:197-199 (Pubitemid 30108094)
25. Thieme K, Turk DC. Heterogeneity of psychophysiological stress responses in fibromyalgia syndrome patients. Arthritis Res Ther 2006;8;R9.
26. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003;48:2916-2922 (Pubitemid 37280621)
27. Holman AJ. Positional cervical spinal cord compression and fibromyalgia: a novel comorbidity with important diagnostic and treatment implications. J Pain 2008;9:613-622
28. Jones KD, Deodhar P, Lorentzen A, Bennett RM, Deodhar AA. Growth hormone perturbations in fibromyalgia: a review. Semin Arthritis Rheum 2007;36:357-379 (Pubitemid 46779123)
29. Crofford LJ, Pillemer SR, Kalogeras KT, et al. Hypothalamic-pituitary- adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994;37:1583-1592 (Pubitemid 24345804)
30. Pruessner JC, Champagne F, Meaney MJ, Dagher A. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci 2004;24:2825-2831 (Pubitemid 38380960)
31. Sullivan RM. Hemispheric asymmetry in stress processing in rat prefrontal cortex and the role of mesocortical dopamine. Stress 2004;7:131-143 (Pubitemid 39013705)
32. Gonera EG, van't Hof M, Berger HJ, van Weel C, Horstink MW. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 1997;12:871-876
33. Katz RS, Leavitt F. Interface between fibromyalgia and attention deficit/hyperactivity disorder [abstract]. Arthritis Rheum 2005;52 Suppl:S76.